血管危险因素和遗传因素与致单基因卒中变异外显率的关联
这项基于英国生物银行454 756名参与者的多中心人群队列研究,分析了NOTCH3、HTRA1和COL4A1/2致病变异与卒中和痴呆的关联。变异携带者卒中风险至少增加66%,且心血管风险负担与变异外显率相关。结果支持控制心血管危险因素可能改善单基因脑小血管病变异携带者的预后。
要点
- NOTCH3、HTRA1和COL4A1/2致病变异在一般人群中比预期更常见,且与卒中和痴呆相关。
- NOTCH3携带者血管性痴呆风险升高(OR 5.42),HTRA1携带者全因痴呆风险升高(OR 2.17),COL4A1/2携带者脑出血风险升高(OR 3.56)。
- 心血管风险负担与NOTCH3和HTRA1携带者的卒中风险增加相关,支持控制心血管危险因素可能改善预后。
核心结论
- 与罕见单基因卒中相关的致病变异在一般人群中比预期更常见,并与卒中和痴呆相关。
- 心血管风险负担与该类变异的外显率相关。
- 结果支持心血管危险因素控制可能改善单基因脑小血管病变异携带者疾病预后的假说。
- 为未来研究评估症状出现前早期识别对减轻卒中和痴呆风险的作用奠定基础。
研究设计与样本
- 多中心人群队列研究,数据来自2006年至2010年招募的英国生物银行参与者,最新随访至2021年9月。
- 纳入454 756名具有全外显子测序及腔隙性卒中相关疾病(卒中、痴呆、偏头痛和癫痫)数据的参与者,排除48 569名数据不完整者。
- 暴露因素为NOTCH3、HTRA1和COL4A1/2致病变异、Framingham心血管风险及缺血性卒中多基因风险。
- 主要结局为现患和 incident 卒中和痴呆;OR和HR均校正年龄、性别、种族、外显子测序批次及前10个遗传主成分。
主要发现
- 454 756名参与者中(208 027名[45.8%]男性;平均[SD]年龄56.5[8.1]岁),973名携带NOTCH3变异,546名携带HTRA1变异,336名携带COL4A1/2变异。
- 变异携带者发生卒中的可能性至少增加66%。
- NOTCH3携带者血管性痴呆风险升高(OR 5.42;95%CI 3.11-8.74),HTRA1携带者全因痴呆风险升高(OR 2.17;95%CI 1.28-3.41),COL4A1/2携带者脑出血风险升高(OR 3.56;95%CI 1.34-7.53)。
- NOTCH3变异与 incident 缺血性卒中和血管性痴呆相关。
- NOTCH3和HTRA1变异与脑小血管病MRI标志物相关;心血管风险负担与NOTCH3和HTRA1携带者的卒中风险增加相关;变异位置也与风险相关。
关键数值与推荐
- NOTCH3携带者血管性痴呆OR 5.42(95%CI 3.11-8.74)。
- HTRA1携带者全因痴呆OR 2.17(95%CI 1.28-3.41)。
- COL4A1/2携带者脑出血OR 3.56(95%CI 1.34-7.53)。
- 变异携带者卒中风险至少增加66%。
临床怎么用
- 原文结论支持心血管危险因素控制可能改善单基因脑小血管病变异携带者的疾病预后。
- 原文结果为未来研究评估症状出现前早期识别对减轻卒中和痴呆风险的作用奠定基础。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It is uncertain whether typical variants causing monogenic stroke are associated with cerebrovascular disease in the general population and why the phenotype of these variants varies so widely. OBJECTIVE: To determine the frequency of pathogenic variants in the 3 most common monogenic cerebral small vessel diseases (cSVD) and their associations with prevalent and incident stroke and dementia. DESIGN, SETTING, AND PARTICIPANTS: This cohort study is a multicenter population-based study of data from UK Biobank participants recruited in 2006 through 2010, with the latest follow-up in September 2021. A total of 9.2 million individuals aged 40 to 69 years who lived in the United Kingdom were invited to join UK Biobank, of whom 5.5% participated in the baseline assessment. Participants eligible for our study (n = 454 756, excluding 48 569 with incomplete data) had whole-exome sequencing and available data pertaining to lacunar stroke-related diseases, namely stroke, dementia, migraine, and epilepsy. EXPOSURES: NOTCH3, HTRA1, and COL4A1/2 pathogenic variants in monogenic stroke; Framingham cardiovascular risk; and ischemic stroke polygenic risk. MAIN OUTCOMES AND MEASURES: Primary outcomes were prevalent and incident stroke and dementia. Odds ratios (ORs) and hazard ratios (HRs) were adjusted for age, sex, ethnicity, exome sequencing batch, and top 10 genetic principal components. RESULTS: Of the 454 756 participants (208 027 [45.8%] men; mean [SD] age, 56.5 [8.1] years), 973 participants carried NOTCH3 variants, 546 carried HTRA1 variants, and 336 carried COL4A1/2 variants. Variant carriers were at least 66% more likely to have had stroke. NOTCH3 carriers had increased vascular dementia risk (OR, 5.42; 95% CI, 3.11-8.74), HTRA1 carriers an increased all-cause dementia risk (OR, 2.17; 95% CI, 1.28-3.41), and COL4A1/2 carriers an increased intracerebral hemorrhage risk (OR, 3.56; 95% CI, 1.34-7.53). NOTCH3 variants were associated with incident ischemic stroke and vascular dementia. NOTCH3 and HTRA1 variants were associated with magnetic resonance imaging markers of cSVD. Cardiovascular risk burden was associated with increased stroke risk in NOTCH3 and HTRA1 carriers. Variant location was also associated with risk. CONCLUSIONS AND RELEVANCE: In this cohort study, pathogenic variants associated with rare monogenic stroke were more common than expected in the general population and associated with stroke and dementia. Cardiovascular risk burden is associated with the penetrance of such variants. Our results support the hypothesis that cardiovascular risk factor control may improve disease prognosis in individuals with monogenic cSVD variants. This lays the foundation for future studies to evaluate the effect of early identification before symptom onset on mitigating stroke and dementia risk.
引用
- Cho BPH, Harshfield EL, Al-Thani M, et al. Association of Vascular Risk Factors and Genetic Factors With Penetrance of Variants Causing Monogenic Stroke. JAMA Neurol. 2022. PMID: 36300346. doi:10.1001/jamaneurol.2022.3832
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。